Vaccine, HiB conjugate vaccine (Meningococcal protein conjugate)

Generic Medicine Info
Indications and Dosage
Prophylaxis of Haemophilus influenzae type B disease in children
Child: Primary immunisation: ActHIB, Hiberix 3 doses of 0.5 mL each, given at 2, 4, 6 months of age. Booster: ActHIB 15-18 months; Hiberix 12 months: 0.5 mL as a single dose. Primary immunisation: PedvaxHIB 2 doses of 0.5 mL each, given at 2, 4 months of age. Booster: 12-15 months 0.5 mL as a single dose.
Hypersensitivity. Acute severe febrile illness.
Special Precautions
Patient with moderate or severe acute illness (with or without fever), bleeding disorders (including thrombocytopaenia), severe immunosuppression. Children. Pregnancy and lactation. Postpone vaccination in case of febrile or acute disease. Not intended for the treatment of Haemophilus influenzae infections.
Adverse Reactions
Significant: Anaphylactoid/hypersensitivity reactions, syncope.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea.
General disorders and administration site conditions: Inj site reactions (e.g. pain, redness, bruising, swelling); fever, irritability, fatigue.
Infections and infestations: Conjunctivitis, otitis media.
Metabolism and nutrition disorders: Loss of appetite.
Psychiatric disorders: Somnolence, nervousness.
Respiratory, thoracic and mediastinal disorders: Upper respiratory tract infection.
Skin and subcutaneous tissue disorders: Rash.
Monitoring Parameters
Monitor for hypersensitivity reactions, 15 minutes after administration.
Drug Interactions
Increased risk of bleeding with anticoagulants. Decreased therapeutic effect and immune response with immunosuppressive therapies (e.g. high dose corticosteroids).
Lab Interference
May interfere with interpretation of urine antigen detection tests.
Description: Haemophilus b (Hib) conjugate vaccine (meningococcal protein conjugate) provides active immunity by inducing production of anticapsular antibodies that protect against infection caused by H. influenzae type b.
Onset: Immunity: Approx 2 weeks.
Duration: Immunity: Antibody concentration >1 mcg/mL: Several years.
Store between 2-8°C. Do not freeze. Protect from light. Any unused portions should be disposed of in accordance with local requirements.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07AG - Haemophilus influenzae B vaccines ; Used for active immunizations.
ActHIB (Sanofi Pasteur Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 07/09/2018.

Anon. Haemophilus b Conjugate Vaccine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 31/07/2018.

Anon. Haemophilus b Vaccine. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 31/07/2018.

Buckingham R (ed). Haemophilus Influenzae Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 31/07/2018.

PedvaxHIB (Merck Sharp & Dohme Corp.). DailyMed. Source: U.S. National Library of Medicine. Accessed 31/07/2018.

Disclaimer: This information is independently developed by MIMS based on Vaccine, HiB conjugate vaccine (Meningococcal protein conjugate) from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in